Evidence map›Paper›PMID 41575337›Full record

ArticleJournal of gynecologic oncology2026

Possible overestimation of treatment effects of pelvic and para-aortic lymphadenectomy for early-stage ovarian clear cell carcinoma: a retrospective propensity-score weighted multi-center cohort study.

Naoki Horikawa, Yoshihide Inayama, Miki Otsuki, Kota Yamauchi, Saya Kiyoshige, Yukiko Taga, Kazuki Yamano, Maki Umemiya, Motonori Matsubara, Yukio Yamanishi and 4 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Naoki Horikawa *Department of Obstetrics and Gynecology, Kurashiki Central Hospital, Kurashiki, Japan.ORCID 0000-0001-8480-6420
Yoshihide Inayama *Department of Gynecology and Obstetrics, Kyoto University Hospital, Kyoto, Japan.ORCID 0000-0003-2040-5913
Miki OtsukiDepartment of Obstetrics and Gynecology, Kitano Hospital, Osaka, Japan.ORCID 0000-0002-5554-6217
Kota YamauchiDepartment of Obstetrics and Gynecology, Kitano Hospital, Osaka, Japan.ORCID 0000-0003-1454-6103
Saya KiyoshigeDepartment of Gynecology, Shiga General Hospital, Moriyama, Japan.ORCID 0009-0006-0473-5700
Yukiko TagaDepartment of Gynecology, Shiga General Hospital, Moriyama, Japan.ORCID 0009-0000-8468-6350
Kazuki YamanoDepartment of Obstetrics and Gynecology, Nagahama Red Cross Hospital, Nagahama, Japan.ORCID 0000-0001-5723-7584
Maki UmemiyaDepartment of Obstetrics and Gynecology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.ORCID 0000-0002-5097-3543
Motonori MatsubaraDepartment of Obstetrics and Gynecology, Toyooka Public Hospital, Toyooka, Japan.ORCID 0009-0006-1747-2401
Yukio YamanishiDepartment of Obstetrics and Gynecology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.ORCID 0009-0005-5010-9228
Takahito AshiharaDepartment of Obstetrics and Gynecology, Osaka Red Cross Hospital, Osaka, Japan.ORCID 0000-0003-1500-4488
Ikuko EmotoDepartment of Obstetrics and Gynecology, Kyoto Medical Center, Kyoto, Japan.ORCID 0000-0003-1427-2675
Masaki MandaiDepartment of Gynecology and Obstetrics, Kyoto University Hospital, Kyoto, Japan.ORCID 0000-0003-4428-8029
Ken YamaguchiDepartment of Gynecology and Obstetrics, Kyoto University Hospital, Kyoto, Japan.ORCID 0000-0002-7669-1405

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe treatment effects of lymphadenectomy in early-stage ovarian clear cell carcinoma (OCCC) reported in previous studies may have been overestimated owing to confounding factors. This study aimed to investigate the treatment effect of pelvic and para-aortic lymphadenectomy (PeNPAN) in early-stage OCCC, with careful adjustment for potential confounders.

methodsThis retrospective multi-center cohort study involved women with preoperatively suspected stage I OCCC. We included patients who underwent surgery for OCCC between 2005 and 2019 at 11 affiliated institutions. The exposure (PeNPAN) group comprised patients who underwent PeNPAN. The primary outcome was disease-free survival (DFS). Additionally, hazard ratios (HRs) of lymphadenectomy for DFS were estimated using unadjusted and propensity score-weighted Cox regression models and biased models applied in previous studies. To identify strong confounders, we further examined factors associated with recurrence that differed between the groups.

resultsWe analyzed 304 women who underwent surgery for preoperatively suspected stage I OCCC. The unadjusted HR for DFS was 0.63 (95% confidence interval [CI]=0.36-1.09; p=0.10), and the propensity-score adjusted HR was 0.82 (95% CI=0.42-1.58; p=0.55). The biased model showed a statistically significant HR of 0.59 (95% CI=0.36-1.00; p=0.048). Adhesions in the Douglas' pouch and cardiovascular disease were associated with recurrence and were more prevalent in the control group, suggesting potential confounders.

conclusionAfter adjusting for potential confounders, the observed treatment effects of lymphadenectomy in the biased models were no longer statistically significant. Future investigations should carefully account for possible confounders, including intraoperative adhesions and comorbidities.

Indexed as

Adenocarcinoma, Clear CellLymph Node ExcisionOvarian NeoplasmsAdultAgedDisease-Free SurvivalFemaleHumansMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPelvisPropensity ScoreRetrospective StudiesTreatment OutcomeComorbidityConfounding FactorsLymphadenectomyOvarian Clear Cell CarcinomaPrognosisTumor

Identifiers

PMID41575337
PMCPMC13009696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.